Is The Oncology Institute, Inc. overvalued or undervalued?

As of 10 May 2023, the valuation grade for The Oncology Institute, Inc. has moved from very attractive to risky, indicating a significant shift in perception regarding its financial health. The company appears to be overvalued given its current metrics, particularly considering its negative P/E ratio and alarming ROE of -1040.97%. The Price to Book Value stands at 48.83, which is exceptionally high, suggesting that investors are paying a premium for the company's assets despite its losses.
In comparison to its peers, The Oncology Institute, Inc. shows a stark contrast with Aveanna Healthcare Holdings, Inc., which has a P/E ratio of 21.61, and Nutex Health, Inc., which is valued as very attractive with a P/E of 4.26. The company's EV to EBITDA ratio of -6.34 further underscores its struggles, particularly when juxtaposed with the industry average. Despite a remarkable YTD return of 641.10%, the overall financial indicators suggest that The Oncology Institute, Inc. is currently overvalued in the market.